We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04729114
Recruitment Status : Recruiting
First Posted : January 28, 2021
Last Update Posted : August 22, 2022
Sponsor:
Information provided by (Responsible Party):
Propella Therapeutics

Brief Summary:
A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer mCRPC mCSPC Drug: PRL-02 Drug: Prednisone Drug: dexamethasone Phase 1 Phase 2

Detailed Description:
This is a Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cancer. In Phase 1 (Dose Escalation), participants will receive i.m. PRL-02 depot in 84-day treatment cycles combined with daily oral steroid, except for one Group, which will evaluate PRL-02 monotherapy (without an oral steroid). In Phase 2a (Dose Expansion), participants with advanced prostate cancer (mCSPC and mCRPC) will be treated with i.m. PRL-02 depot at one or more RP2Ds selected from Phase 1 in 84-day treatment cycles in combination with dexamethasone. In both phases, participants will undergo scheduled periodic assessments of serum testosterone levels.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: This is a 3+3 dose escalation study design with a dose expansion phase once a Phase 2 dose is identified.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2a, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Actual Study Start Date : June 14, 2021
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : April 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Cohort 1
180 mg PRL-02 + dexamthasone or prednisone
Drug: PRL-02
abiraterone decanoate for intramuscular injection

Drug: Prednisone
5 mg once daily or twice daily

Drug: dexamethasone
0.5 mg administered once daily

Experimental: Cohort 2
360 mg PRL-02 + dexamthasone or prednisone
Drug: PRL-02
abiraterone decanoate for intramuscular injection

Drug: Prednisone
5 mg once daily or twice daily

Drug: dexamethasone
0.5 mg administered once daily

Experimental: Cohort 3
720 mg PRL-02 + dexamthasone or prednisone
Drug: PRL-02
abiraterone decanoate for intramuscular injection

Drug: Prednisone
5 mg once daily or twice daily

Drug: dexamethasone
0.5 mg administered once daily

Experimental: Cohort 4
1260 mg PRL-02 + dexamthasone or prednisone
Drug: PRL-02
abiraterone decanoate for intramuscular injection

Drug: Prednisone
5 mg once daily or twice daily

Drug: dexamethasone
0.5 mg administered once daily

Experimental: Cohort 5
1800 mg PRL-02 + dexamthasone or prednisone
Drug: PRL-02
abiraterone decanoate for intramuscular injection

Drug: Prednisone
5 mg once daily or twice daily

Drug: dexamethasone
0.5 mg administered once daily




Primary Outcome Measures :
  1. Safety (adverse events) [ Time Frame: Treatment ]
    Determine the incidence rates for adverse events using NCI CTCAE v5.0 grading through study completion, an average of 1 year

  2. Determination of recommended Phase 2 dose (RP2D) [ Time Frame: Treatment ]
    Select RP2D of PRL-02 depot by evaluation of safety parameters up to 84 days

  3. Testosterone suppression [ Time Frame: Treatment ]
    Number of subjects with testosterone suppression to </= 1 ng/dL or >/90% reduction up to 84 days


Secondary Outcome Measures :
  1. Evaluate pharmacokinetics (PK) profile of PRL-02 [ Time Frame: Treatment ]
    Determination of PK profiles of PRL-02 up to 84 days



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent obtained prior to any study-related procedure being performed.
  2. Male patients at least 18 years of age or older at time of consent.
  3. Histological evidence of adenocarcinoma of the prostate.
  4. Patients must have one of the following documented conditions:

    • Metastatic castration sensitive prostate cancer (mCSPC);
    • Castration sensitive prostate cancer (CSPC) with biochemical relapse (using the Prostate Cancer Working Group 3 [PCWG3] definition of PSA progression) of prostate cancer;
    • Castration sensitive prostate cancer (CSPC) with oligometastatic prostate cancer (e.g., Positron Emission Tomography (PET) positive);
    • Metastatic castration resistant prostate cancer (mCRPC);

    Patients screened under protocol amendment 4 - Patients with one or more of the following:

    • CTC count of ≥5 cells/7.5 mL blood at screening confirmed by the central laboratory
    • Measurable disease according to RECIST v1.1 and a target lesion ≥1 cm in size at screening
    • PSA value ≥2 µg/L (2 ng/mL) at screening
    • Expansion Groups D and E: mCRPC and prior exposure to either abiraterone or enzalutamide
  5. Undergone orchiectomy or ongoing GnRH agonist or antagonist therapy for at least 1 month prior to the Screening Visit.
  6. A serum testosterone level <50 ng/dL but greater than or equal to 2 ng/dL at screening.
  7. Adequate muscle mass for an intramuscular injection
  8. An Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  9. Adequate bone marrow reserve defined as:

    • Absolute neutrophil count (ANC) greater than or equal to 1500/µL
    • Platelet greater than or equal to 100,000/µL
    • Hemoglobin greater than or equal to 9gm/dL
  10. Adequate renal function defined as a serum creatinine less than or equal to 1.5 x upper limit of normal (ULN) for the reference laboratory or a calculated creatinine clearance great than or equal to 50mL/min as determined by a validated algorithm for calculating creatinine clearance.
  11. Adequate hepatic function defined as ALT and AST less than or equal to 2.5 x ULN and total bilirubin less than or equal to 1.5 x ULN. Exception for elevated bilirubin secondary to Gilbert's disease. Confirmation of Gilbert's diagnosis requires: elevated unconjugated (indirect) bilirubin values; normal complete blood count in previous 12 months, blood smear, and reticulocyte count; normal aminotransferases and alkaline phosphatase in previous 12 months.
  12. Serum albumin greater than or equal to 3gm/dL and serum potassium greater than or equal to 3.5 mEq/L.
  13. Patients who are non-sterile and who are heterosexually active with a female partner of childbearing potential must be willing to use a highly effective means of contraception, such as a male condom plus spermicide, from the time of screening, throughout the total duration of the drug treatment, and until 12 weeks after the final dose of study drug.
  14. Phase 1 Expansion Groups D and E: Patients must have received prior abiraterone or enzalutamide respectively with documented evidence of progression with one or more of the following:

    • PSA progression defined per PCWG3 criteria (Scher 2016) as ≥2 occurrences of rising PSA with a minimum of 1 week and a PSA concentration of ≥1 ng/mL if confirmed PSA rise is the only measure of progression OR worsening measurable disease on computed tomography (CT)/magnetic resonance imaging (MRI) per RECIST v1.1 criteria or at least one new documented lesion on a bone scan.

  15. Patients Screened Under Protocol Amendment 4: Evidence of radiographic progression of metastatic disease at study entry, as assessed by the investigator, defined as measurable disease on CT/MRI per RECIST v1.1 or at least one documented bone lesion on a bone scan. Patients whose disease is limited to regional pelvic lymph nodes or local recurrence (e.g bladder, rectum) are not eligible.

Exclusion Criteria:

  1. Patients with metastatic castration resistant prostate cancer (mCRPC) more than minimally symptomatic or with a reported pain score on an 11-point (0 - 10) numeric rating scale of >3 over the previous 7 days.
  2. Known active central nervous system (CNS) metastases. Patients with CNS metastases that have been treated with surgery and/or radiation therapy, who are off pharmacologic doses of glucocorticoids, and who are neurologically stable are eligible.
  3. Impending bone fracture due to bone metastases
  4. Has a known additional malignancy beyond prostate cancer that required active treatment with the exception of any of the following:

    • Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ carcinoma of any type
    • Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for ≥2 years
    • Any other cancer from which the patient has been disease-free for ≥5 years The Medical Monitor should be contacted for any questions regarding this exclusion criterion.
  5. Clinically significant cardiac disease, defined as any of the following:

    • Clinically significant cardiac arrhythmias including bradyarrhythmia and/or subjects who require anti-arrhythmic therapy (excluding beta blockers or digoxin). Subjects with controlled atrial fibrillation are not excluded.
    • Congenital long QT syndrome
    • QT interval corrected by Fredericia's formula (QTcF) ≥450 msec at screening (based on average of triplicate electrocardiograms [ECGs] at baseline). If the QT interval corrected for heart rate intervals (QTc) is prolonged in a patient with a pacemaker or bundle branch block, the patient may be enrolled in the study if confirmed by the Medical Monitor.
    • History of clinically significant cardiac disease or congestive heart failure >New York Heart Association Class II or left ventricular ejection fraction measurement of <50% at baseline. Patients must not have unstable angina (symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months [NYHA Classification 2014].
    • Uncontrolled hypertension, defined as systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg which has been confirmed by 2 successive measurements despite optimal medical management.
    • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the 3 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring >1 month before the start of study medication).
  6. Participated in an investigational drug study within 5 half-lives of the investigational drug or within 4 weeks of the Screening Visit, whichever is shorter
  7. Any unresolved National Cancer Institute (NCI) CTCAE criteria v5.0 Grade >2 toxicity from previous anticancer therapy at the Screening Visit. Patients receiving ongoing replacement hormone therapy for endocrine immune-related AEs without clinical symptoms will not be excluded.
  8. Has not recovered from recent major surgery or trauma
  9. Received a blood transfusion within 2 weeks of the Screening Visit
  10. History of impaired pituitary or adrenal gland function (e.g., Addison's disease, Cushing's syndrome)
  11. Prior treatment with abiraterone, orteronel, or current treatment with systemic ketoconazole or any other CYP17 inhibitor. Exception: patients in Phase 1 Expansion Group D will have received prior abiraterone.
  12. Current treatment with enzalutamide, flutamide, nilutamide, bicalutamide, or any other androgen receptor (AR) blocking agents. Patients who have received anti-androgens or AR blocking agents must have discontinued bicalutamide ≥6 weeks and other antiandrogens ≥4 weeks prior to the Screening Visit.
  13. Prior treatment with estrogens within the previous 3 months
  14. Need for systemic glucocorticoids greater than replacement doses; the use of topical, intraocular, inhalational, intranasal, or intra-articular glucocorticoids is permitted.
  15. Prior use of any herbal products that could decrease PSA levels (e.g., saw palmetto) within 30 days of the Screening Visit. Patient must agree not to use such herbal products during study participation.
  16. Use of biotin (i.e., vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg [NIH-ODS 2021]. Note: Patients who switch from a high dose to a dose of 30 µg/day or less are eligible for study entry.
  17. Required concomitant use of strong inducers of CYP3A4.
  18. Known hypersensitivity to PRL-02, abiraterone, abiraterone decanoate, prednisone, or dexamethasone or any of their excipients or components.
  19. Has jaundice or known current active liver disease from any cause, including hepatitis A (hepatitis A virus immunoglobulin M [IgM] positive), hepatitis B (hepatitis B virus surface antigen [HbsAg] positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid).
  20. Hemoglobin A1c (HbA1c) >10% in patients previously diagnosed with diabetes mellitus. HbA1c >8% in patients whose diabetes mellitus is previously undiagnosed. (Excluded patients may be rescreened after referral and evidence of improved control of their condition).
  21. Uncontrolled infection with human immunodeficiency virus (HIV+). Exception: patients with well-controlled HIV (e.g., CD4 >350/mm3 and undetectable viral load) are eligible.
  22. Body mass index >40 kg/m2.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04729114


Contacts
Layout table for location contacts
Contact: Mike Sterba 415-652-3494 msterba@consultingjw.com

Locations
Layout table for location information
United States, Indiana
First Urology Recruiting
Jeffersonville, Indiana, United States, 47130
Contact: Debbie Johnson, CCRC         
Principal Investigator: James Bailen, MD         
United States, Maryland
Chesapeake Urology Recruiting
Towson, Maryland, United States, 21204
Contact: Erica Boroshok         
Principal Investigator: Ronald Tutrone, MD         
United States, Nebraska
GU Research Recruiting
Omaha, Nebraska, United States, 68130
Contact: Heather Mittelstedt, RN         
Principal Investigator: Luke Nordquist, MD         
United States, New Mexico
Xcancer/NM Oncology Recruiting
Albuquerque, New Mexico, United States, 87109
Contact: Sarah Tellez         
Principal Investigator: Jose Avitia, MD         
United States, Pennsylvania
Centers for Advanced Urology, LLP, d/b/a: MidLantic Urology Recruiting
Bala-Cynwyd, Pennsylvania, United States, 19004
Contact: Laurence Belkoff, MD    610-667-0458    czinar@ucsepa.com   
Contact: Cheryl Zinar    6106670458    czinar@ucsepa.com   
Principal Investigator: Laurence M Belkoff         
United States, South Carolina
Carolina Urologic Research Center Recruiting
Myrtle Beach, South Carolina, United States, 29572
Contact: Jennifer Sutton, RN         
United States, Tennessee
Urology Associates PC Recruiting
Nashville, Tennessee, United States, 37209
Contact: David Morris, MD       dmorris@ua-pc.com   
Principal Investigator: David A Morris         
United States, Texas
Urology San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Clara De La Cruz    210-617-4116      
Contact: Emily Robb    12106174116      
Principal Investigator: Jose De La Cerda, MD         
Sponsors and Collaborators
Propella Therapeutics
Investigators
Layout table for investigator information
Study Director: Jackie Walling, MBChB, Ph.D Consulting JW, LLC/Propella Therapeutics
Layout table for additonal information
Responsible Party: Propella Therapeutics
ClinicalTrials.gov Identifier: NCT04729114    
Other Study ID Numbers: PRL-02-1001
First Posted: January 28, 2021    Key Record Dates
Last Update Posted: August 22, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Propella Therapeutics:
Testosterone
Testosterone suppression
metastatic castrate sensitive prostate cancer
metastatic castrate resistant prostate cancer
metastatic disease
prostate cancer
mCSPC
mCRPC
abiraterone
abiraterone decanoate
abiraterone acetate
Phase 1/2a
Propella
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Dexamethasone
Prednisone
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents